Semaglutide is well tolerated without hazard of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse results. A sizable populace influenced with COVID-19 an infection have been diabetic; therefore use of semaglutide in diabetes and CV sufferers might be very much supportive in maintaining wellbeing treatment method all through this pandemic https://marlonn887cny1.blue-blogs.com/profile